ArticleAnnals of medicine and surgery (2012)2025
Efficacy and safety of azithromycin in treating sinusitis patients: a systematic review and meta-analysis of randomized controlled trails.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sinusitis is an inflammation of the paranasal sinuses and is commonly treated with antibiotics. The widely used antibiotics for this condition are macrolides, especially azithromycin. However, its effectiveness and side effects are still questionable compared to the other antibiotics. Therefore, this systematic review and meta-analysis assessed the efficacy and safety profile of azithromycin in sinusitis. Methods: We adhered to PRISMA guidelines. A comprehensive literature review was performed to find out about randomized controlled trials concerning azithromycin compared with other antibiotics in sinusitis treatment. The main outcomes were the cure rate, pathogen eradication rate, and relapse rate. The secondary outcome was the adverse events rate. Results: Fourteen trials were considered for review, with a sample size of 4201 patients. The pooled analysis for included studies indicated a high cure rate (70.86%) and pathogen eradication rate (74.55%), as well as a low relapse rate (4.82%) and adverse events rate (14.33%) for azithromycin in treating sinusitis patients. The quality of the included studies was considered to be moderate. In a meta-analysis, azithromycin demonstrated superiority in the cure rate to other antibiotics in the study but no difference in pathogen eradication rate, relapse rate, or adverse events rate. Conclusion: Our results showed promising efficacy and safety of azithromycin in the management of sinusitis patients. However, moderate heterogeneity among studies and a 14.33% rate of adverse effects, primarily gastrointestinal, indicate the importance of individualized treatment decisions. Further research is needed to address variability and optimize its clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.